OrthoPediatrics reported 1Q19 revenue of USD $14.7MM, +21.2% vs. 1Q18.
- Reiterated 2019 guidance of $69.7MM to 70.9MM, or 21% to 23% growth with expected consignment set investment of $15MM to $17MM
- Deployed $2.7MM in consignment sets in 1Q19, in anticipation of summer surgery season
- Launched BandLoc DUO to add to BandLoc 5.5/6.0mm System
- Added seven new U.S. sales representatives, bringing total force to 138
- Converted Belgium and the Netherlands to sales agency model
Segment sales and growth on an as-reported basis ($MM):
1Q19 | 1Q18 | $ Chg | % Chg | |
Spine | $4.3 | $2.7 | $1.6 | 58.6% |
Trauma | $10.0 | $9.1 | $0.9 | 9.8% |
Sports Medicine | $0.4 | $0.3 | $0.1 | 33.2% |
Total | $14.7 | $12.1 | $2.6 | 21.2% |
Revenue by geographic region ($MM):
Geographic Region | 1Q19 | 1Q18 | $ Chg | % Chg |
US | $10.3 | $8.7 | $1.6 | 18.7% |
Ex-US | $4.4 | $3.4 | $0.9 | 27.6% |
Total | $14.7 | $12.1 | $2.6 | 21.2% |
Net earnings ($MM):
1Q19 | Amount | % of Sales |
Sales | $14.7 | |
  Cost of Sales | -$4.0 | 27.3% |
  General and Admin | -$5.6 | 38.3% |
  Selling and Marketing | -$6.5 | 44.7% |
  R & D | -$1.2 | 8.3% |
  Other | -$0.3 | 2.1% |
Net Earnings | -$3.0 | -20.6% |
Source: OrthoPediatrics
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
OrthoPediatrics reported 1Q19 revenue of USD $14.7MM, +21.2% vs. 1Q18.
Reiterated 2019 guidance of $69.7MM to 70.9MM, or 21% to 23% growth with expected consignment set investment of $15MM to $17MM
Deployed $2.7MM in consignment sets in 1Q19, in anticipation of summer surgery season
Launched BandLoc DUO to add to BandLoc...
OrthoPediatrics reported 1Q19 revenue of USD $14.7MM, +21.2% vs. 1Q18.
- Reiterated 2019 guidance of $69.7MM to 70.9MM, or 21% to 23% growth with expected consignment set investment of $15MM to $17MM
- Deployed $2.7MM in consignment sets in 1Q19, in anticipation of summer surgery season
- Launched BandLoc DUO to add to BandLoc 5.5/6.0mm System
- Added seven new U.S. sales representatives, bringing total force to 138
- Converted Belgium and the Netherlands to sales agency model
Segment sales and growth on an as-reported basis ($MM):
1Q19 | 1Q18 | $ Chg | % Chg | |
Spine | $4.3 | $2.7 | $1.6 | 58.6% |
Trauma | $10.0 | $9.1 | $0.9 | 9.8% |
Sports Medicine | $0.4 | $0.3 | $0.1 | 33.2% |
Total | $14.7 | $12.1 | $2.6 | 21.2% |
Revenue by geographic region ($MM):
Geographic Region | 1Q19 | 1Q18 | $ Chg | % Chg |
US | $10.3 | $8.7 | $1.6 | 18.7% |
Ex-US | $4.4 | $3.4 | $0.9 | 27.6% |
Total | $14.7 | $12.1 | $2.6 | 21.2% |
Net earnings ($MM):
1Q19 | Amount | % of Sales |
Sales | $14.7 | |
  Cost of Sales | -$4.0 | 27.3% |
  General and Admin | -$5.6 | 38.3% |
  Selling and Marketing | -$6.5 | 44.7% |
  R & D | -$1.2 | 8.3% |
  Other | -$0.3 | 2.1% |
Net Earnings | -$3.0 | -20.6% |
Source: OrthoPediatrics
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.